Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pulmonx (LUNG) EBITDA (2019 - 2025)

Historic EBITDA for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to -$14.4 million.

  • Pulmonx's EBITDA fell 568.36% to -$14.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$57.0 million, marking a year-over-year decrease of 94.13%. This contributed to the annual value of -$56.9 million for FY2024, which is 477.94% up from last year.
  • Latest data reveals that Pulmonx reported EBITDA of -$14.4 million as of Q3 2025, which was down 568.36% from -$14.7 million recorded in Q2 2025.
  • Over the past 5 years, Pulmonx's EBITDA peaked at -$10.1 million during Q3 2021, and registered a low of -$16.1 million during Q1 2022.
  • Over the past 5 years, Pulmonx's median EBITDA value was -$14.4 million (recorded in 2025), while the average stood at -$14.1 million.
  • As far as peak fluctuations go, Pulmonx's EBITDA crashed by 16433.24% in 2021, and later skyrocketed by 891.23% in 2024.
  • Quarter analysis of 5 years shows Pulmonx's EBITDA stood at -$12.8 million in 2021, then decreased by 9.87% to -$14.1 million in 2022, then increased by 6.47% to -$13.2 million in 2023, then dropped by 3.06% to -$13.6 million in 2024, then decreased by 5.58% to -$14.4 million in 2025.
  • Its last three reported values are -$14.4 million in Q3 2025, -$14.7 million for Q2 2025, and -$14.4 million during Q1 2025.